Clinic
Ramesh Moolani, MD INC
Ramesh Moolani, MD INC was paid $1.52M by Medicaid between Mar 2022 and Dec 2024, across 24 billing codes. Its largest line is J9306, Injection, pertuzumab, 1 mg — 36% of everything it billed.
33Billing provider infoRAMESH MOOLANI, MD INC
CHULA VISTA, CA 91911
CHULA VISTA, CA 91911
33aNPI1366197956assigned 02/14/2022
33bProvider typeHealth Service Clinic/Center
28Total paid$1.52M
24GClaims9,395
24DCodes billed24
24AFirst – last monthMar 2022 – Dec 2024
Compared with peers
Next to other Health Service Clinic/Center providers in California
Rank by total paid#14 of 87
Median peer was paid$88K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 1,353 | $35K | |
| 2023 | 2,930 | $121K | |
| 2024incomplete | 5,112 | $1.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9306 | Injection, pertuzumab, 1 mg | 36% | 90 | 63 | $544K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 22% | 266 | 188 | $339K |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 13% | 77 | 53 | $196K |
| J9271 | Injection, pembrolizumab, 1 mg | 12% | 19 | 14 | $181K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.4% | 1,567 | 1,015 | $67K |
| 96367 | 2.6% | 769 | 510 | $39K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.5% | 950 | 915 | $38K |
| 96417 | 2.1% | 771 | 496 | $31K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 1,096 | 719 | $24K |
| J9202 | Goserelin acetate implant, per 3.6 mg | 1.3% | 25 | 25 | $20K |
| 96368 | <1% | 554 | 334 | $9K | |
| 96415 | <1% | 176 | 128 | $8K |
12 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 264 | $6K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 75 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 73 | $4K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 306 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 32 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 352 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 854 | $2K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 61 | $1K |
| 96402 | <1% | 59 | $507.59 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 13 | $313.89 |
| 36415 | Collection of venous blood by venipuncture | <1% | 863 | $125.40 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 83 | $90.19 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOOLANI, RAMESH (CEO)